Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan

Yoichi Oikawa, Akira Shimada, Mizumi Kyo

.
Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

DOI: 10.4236/ojemd.2013.35034                

Abstract

Introduction: It was recently reported that candesartan, an angiotensin II receptor blocker, had a protective effect against cardiovascular events, comparable to that of calcium channel antagonists. Moreover, a renoprotective effect and anti-diabetic action of candesartan had also been demonstrated. However, whether the renoprotective effect of candesartan, especially in diabetes, was dose-dependent or not remain to be fully elucidated. The present study attempted to clarify the dose effect of renoprotection by candesartan in Japanese type 2 diabetic patients. Subjects and Method: In this case series study, we recruited 26 type 2 diabetic patients with albuminuria whose blood pressure did not reach the target BP level (<130/80 mmHg) despite administration of 4 or 8 mg/day of candesartan. Subsequently, these lower doses of candesartan were increased to the maximal dose in Japan, 12 mg/day. Clinical parameters were examined before, at 6 and 12 months after the increase in dose. Results: An ameliorating effect of the increased dose of candesartan on albuminuria and hypertension was distinctly observed. No severe adverse effect was observed. Conclusion: It was highly possible that the maximal dose of candesartan provided more effective renoprotection in hypertensive type 2 diabetic patients initially treated with lower doses of candesartan.

Keywords

Albuminuria; Angiotensin II Receptor Blocker (ARB); Candesartan; Hypertension; Type 2 Diabetes

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	W. B. Kannel and D. L. McGee, “Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: the Framingham Study,” Diabetes Care, Vol. 2, No. 2, 1979, pp. 120-126. doi:10.2337/diacare.2.2.120
[2]	H. C. Gerstein, J. F. Mann, Q, Yi, B. Zinman, S. F. Dinneen, B. Hoogwerf, J. P. Hallé, J. Young, A. Rashkow, C. Joyce, S. Nawaz and S. Yusuf; HOPE Study Investigators, “Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals,” JAMA, Vol. 286, No. 4, 2001, pp. 421-426. doi:10.1001/jama.286.4.421
[3]	M. Hayashi, “Development of New Therapies, Including Regeneration of the Kidney, for Chronic Kidney Diseases,” Clinical and Experimental Nephrology, Vol. 10, No. 2, 2006, pp. 99-101. doi:10.1007/s10157-006-0418-7
[4]	Japanese Society of Hypertension Committee, “The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009),” Hypertension Research, Vol. 32, No. 1, 2009, pp. 3-107.
[5]	V. Dzau, “The Cardiovascular Continuum and Renin-Angiotensin-Aldosterone System Blockade,” Journal of Hypertension—Supplement, Vol. 23, No. 1, 2005, pp. S9-S17. doi:10.1097/01.hjh.0000165623.72310.dd
[6]	E. J. Lewis, L. G. Hunsicker, W. R. Clarke, T. Berl, M. A. Pohl, J. B. Lewis, E. Ritz, R. C. Atkins, R. Rohde and I. Raz; Collaborative Study Group, “Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes,” The New England Journal of Medicine, Vol. 345, No. 12, 2001, pp. 851-860. doi:10.1056/NEJMoa011303
[7]	M. A. Pfeffer, K. Swedberg, C. B. Granger, P. Held, J. J. McMurray, E. L. Michelson, B. Olofsson, J. Ostergren, S and Yusuf and S. Pocock; CHARM Investigators and Committees, “Effects of Candesartan on Mortality and Morbidity in Patients with Chronic Heart Failure: the CHARM-Overall Programme,” Lancet, Vol. 362, No. 9386, 2003, pp. 759-766. doi:10.1016/S0140-6736(03)14282-1
[8]	H. Makino, M. Haneda, T. Babazono, T. Moriya, S. Ito, Y. Iwamoto, R. Kawamori, M. Takeuchi and S. Katayama; INNOVATION Study Group, “Prevention of Transition from Incipient to Overt Nephropathy with Telmisartan in Patients with Type 2 Diabetes,” Diabetes Care, Vol. 30, No. 6, 2007, pp. 1577-1578. doi:10.2337/dc06-1998
[9]	T. Ogihara, K. Nakao, T. Fukui, K. Fukiyama, K. Ueshima, K. Oba, T. Sato and T. Saruta; Candesartan Anti-hypertensive Survival Evaluation in Japan Trial Group, “Effects of Candesartan Compared with Amlodipine in Hypertensive Patients with High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial,” Hypertension, Vol. 51, No. 2, 2008, pp. 393-398. doi:10.1161/HYPERTENSIONAHA.107.098475
[10]	T. Saruta, K. Hayashi, T. Ogihara, K. Nakao, T. Fukui and K. Fukiyama; CASE-J Study Group, “Effects of Candesartan and Amlodipine on Cardiovascular Events in Hypertensive Patients with Chronic Kidney Disease: Subanalysis of the CASE-J Study,” Hypertension Research, Vol. 32, No. 6, 2009, pp. 505-512. doi:/10.1038/hr.2009.44
[11]	F. Locatelli, L. Del Vecchio and A. Cavalli, “Inhibition of the Renin-Angiotensin System in Chronic Kidney Disease: A Critical Look to Single and Dual Blockade,” Nephron Clinical Practice, Vol. 113, No. 4, 2009, pp. c286-c293. doi:10.1159/000235946
[12]	K. Rossing, P. K. Christensen, B. V. Hansen, B. Carstensen and H. H. Parving, “Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients with Nephropathy: A Double-Blind Randomized Cross-Over Study,” Diabetes Care, Vol. 26, No. 1, 2003, pp. 150-155. doi:10.2337/diacare.26.1.150
[13]	D. de Zeeuw, G. Remuzzi, H.H. Parving, W. F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M. E. Cooper, W. E. Mitch and B. M. Brenner, “Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients with Nephropathy,” Circulation, Vol. 110, No. 8, 2004, pp. 921-927. doi:10.1161/01.CIR.0000139860.33974.28
[14]	H. Ibsen, M. H. Olsen, K. Wachtell, K. Borch-Johnsen, L. H. Lindholm, C. E. Mogensen, B. Dahlof, R. B. Devereux, U. de Faire, F. Fyhrquist, S. Julius, S. E. Kjeldsen, O. Lederballe-Pedersen, M. S. Nieminen, P. Omvik, S. Oparil and Y. Wan, “Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study,” Hypertension, Vol. 45, No. 2, 2005, pp. 198-202. doi:10.1161/01.HYP.0000154082.72286.2a
[15]	J. V. Lozano, J. L. Llisterri, J. Aznar and J. Redon; Spanish Working Group, “Losartan Reduces Microalbuminuria in Hypertensive Microalbuminuric Type 2 Diabetics,” Nephrology Dialysis Transplantation, Vol. 16, Suppl. 1, 2001, pp. 85-89. doi:10.1093/ndt/16.suppl_1.85
[16]	P. Bramlage, D. Pittrow and W. Kirch, “The Effect of Irbesartan in Reducing Cardiovascular Risk in Hypertensive Type 2 Diabetic Patients: An Observational Study in 16,600 Patients in Primary Care,” Current Medical Research and Opinion, Vol. 20, No. 10, 2004, pp. 1625-1631. doi:10.1185/030079904X3861
[17]	S. E. Kjeldsen, S. Julius, G. Mancia, G. T. McInnes, T. Hua, M. A. Weber, A. Coca, S. Ekman, X. Girerd, K. Jamerson, P. Larochelle, T. M. MacDonald, R. E. Schmieder, M. A. Schork, P. Stolt, R. Viskoper, J. Widimsky and A. Zanchetti; VALUE Trial Investigators, “Effects of Valsartan Compared to Amlodipine on Preventing Type 2 Diabetes in High-Risk Hypertensive Patients: The VALUE Trial,” Journal of Hypertension, Vol. 24, No. 7, 2006, pp. 1405-1412. doi:10.1097/01.hjh.0000234122.55895.5b
[18]	R. H. Rao, “Pressor Doses of Angiotensin II Increase Hepatic Glucose Output and Decrease Insulin Sensitivity in Rats,” Journal of Endocrinology, Vol. 148, No. 2, 1996, pp. 311-318. doi:10.1677/joe.0.1480311
[19]	T. Ogihara, T. Asano, K. Ando, Y. Chiba, H. Sakoda, M. Anai, N. Shojima, H. Ono, Y. Onishi, M. Fujishiro, H. Katagiri, Y. Fukushima, M. Kikuchi, N. Noguchi, H. Aburatani, I. Komuro and Y. Fujita, “Angiotensin II-Induced Insulin Resistance Is Associated with Enhanced Insulin Signaling,” Hypertension, Vol. 40, No. 6, 2002, pp. 872-879. doi:10.1161/01.HYP.0000040262.48405.A8
[20]	O. Eshoj, B. Feldt-Rasmussen, M. L. Larsen and E. F. Mogensen, “Comparison of Overnight, Morning and 24-Hour Urine Collections in the Assessment of Diabetic Microalbuminuria,” Diabetic Medicine, Vol. 4, No. 6, 1987, pp. 531-533. doi:10.1111/j.1464-5491.1987.tb00924.x